Retinol-binding protein 4 (RBP4) as the causative factor and marker of vascular injury related to insulin resistance
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2016, Vol 70, Issue
Abstract
One of adipokines involved in the development of insulin resistance is retinol-binding protein 4(RBP4). The physiological role of RBP4 is transport of retinol from the liver to peripheral tissues. One of the first events related to the excessive visceral fat accumulation is the development of inflammation followed by hormonal adipose tissue dysfunction, including excessive RBP4 production. Reduced density of the membrane-type glucose transporter 4 (GLUT4) is considered as a direct cause for the stimulation of RBP4 release to the circulation by adipocytes. Circulating RBP4 inhibits the signal pathways stimulated by insulin in skeletal muscle cells, resulting in the development of insulin resistance. Drugs stimulating receptor peroxisome proliferator-activated gamma (PPARγ) – thiazolidinediones – inhibit the production of RBP4 by adipose tissue and increase the insulin sensitivity of the tissues. Increased secretion of RBP4 stimulates the expression of adhesion molecules in the endothelial cells, promoting development of atherosclerosis and arterial hypertension. Population studies demonstrated an association between serum RBP4 in the circulation, and the severity of atherosclerosis and risk of the cardiovascular events and type 2 diabetes. It also appears that the rbp4 gene functional polymorphisms may influence the risk of metabolic complications of obesity, including vascular injury. Therefore, the concentration of RBP4 in the circulation may be considered both as the causative factor and marker of chronic vascular injury. This article summarizes the current state of knowledge on the potential role of RBP4 in the pathogenesis of cardiovascular diseases, particularly related to insulin resistance.
Authors and Affiliations
Marcin Majerczyk, Magdalena Olszanecka-Glinianowicz, Monika Puzianowska-Kuźnicka, Jerzy Chudek
Keywords
Related Articles
- EP ID EP206133
- DOI -
- Views 129
- Downloads 0
HMGB1 – its role in tumor progression and anticancer therapy
HMGB1 is an evolutionarily conserved protein with a wide spectrum of action. Its main receptors are RAGE and TLR found on the surface of immune system cells as well as endothelial cells. Although signaling pathways for b...
Stygmatyzacja w dermatologii ze szczególnym uwzględnieniem chorych na łuszczycę
A stigma is currently defined as a discrediting mark, biological or social, that sets a person off from others and disrupts interactions with them. People who differ from social norms in some respect are often negatively...
Current perspectives on the use of miRNA as a biomarker for EGFR-targeted therapy for non-small cell lung cancer
Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer in the world. Currently, a large number of research studies are conducted to develop and implement new treatment strategies. Intensive efforts...
Insulinooporność a przewlekła reakcja zapalna
Insulinooporność jest stanem zmniejszonej odpowiedzi biologicznej tkanek na insulinę. Badania ostatnich lat spowodowały wzrost zainteresowania rolą przewlekłej reakcji zapalnej o niskiej aktywności w patogenezie insulino...
The role of glucose transporter 1 (GLUT1) in the diagnosis and therapy of tumors
Malignant cells are known to enhance glucose metabolism, to increase glucose uptake and to inhibit the process of oxidative phosphorylation. Accelerated glycolysis is one of the biochemical characteristics of cancer c...